Pioglitazone upregulates adiponectin receptor 2 in 3T3-L1 adipocytes

Life Sciences

Volumn 88, Issue 23-24, 2011, Pages 1055-1062

  Kudoh, Akihiro ^a   Satoh, Hiroaki ^a   Hirai, Hiroyuki ^a   Watanabe, Tsuyoshi ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

AdipoR2; AMPK; Pioglitazone; PPAR

Indexed keywords

ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PIOGLITAZONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; CELL STRAIN 3T3; GLUCOSE TRANSPORT; INSULIN RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARACRINE SIGNALING; PROTEIN PHOSPHORYLATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

3T3-L1 CELLS; ADIPOCYTES; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; DEOXYGLUCOSE; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; MICE; PHOSPHORYLATION; PPAR GAMMA; RECEPTORS, ADIPONECTIN; RNA, MESSENGER; THIAZOLIDINEDIONES; UP-REGULATION;

ADENOVIRIDAE;

EID: 79957580709     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2011.04.001     Document Type: Article

References (41)

1. Auboeuf D, Rieusset J, Fajas L, Vallier P, Frering V, Riou JP, et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 1997;46(8):1319-27. (Pubitemid 27315281)
2. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001;7(8):947-53.
3. Caminos JE, Nogueiras R, Gallego R, Bravo S, Tovar S, Garcia-Caballero T, et al. Expression and regulation of adiponectin and receptor in human and rat placenta. J Clin Endocrinol Metab 2005;90(7):4276-86. (Pubitemid 41058209)
4. Coletta DK, Sriwijitkamol A, Wajcberg E, Tantiwong P, Li M, Prentki M, et al. Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial. Diabetologia 2009;52(4):723-32.
5. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366(9493): 1279-89. (Pubitemid 41416583)
6. Fisher JS, Gao J, Han DH, Holloszy JO, Nolte LA. Activation of AMP kinase enhances sensitivity of muscle glucose transport to insulin. Am J Physiol Endocrinol Metab 2002;282(1):E18-23.
7. Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell 2004;116(2):337-50. (Pubitemid 38167322)
8. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A 2001;98(4):2005-10. (Pubitemid 32165613)
9. Hirose H, Kawai T, Yamamoto Y, Taniyama M, Tomita M, Matsubara K, et al. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanesemale patients with type 2 diabetes. Metabolism2002;51(3): 314-7.
10. Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC, et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001;50(5):1126-33. (Pubitemid 32374544)
11. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996;271(18):10697-703. (Pubitemid 26145805)
12. Iglesias MA, Ye JM, Frangioudakis G, Saha AK, Tomas E, Ruderman NB, et al. AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats. Diabetes 2002;51(10):2886-94.
13. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995;270(22):12953-6.
14. Li W, Tonelli J, Kishore P, Owen R, Goodman E, Scherer PE, et al. Insulin-sensitizing effects of thiazolidinediones are not linked to adiponectin receptor expression in human fat or muscle. Am J Physiol Endocrinol Metab 2007;292(5):E1301-7.
15. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996;221(2):286-9. (Pubitemid 26136463)
16. Nakano Y, Tobe T, Choi-Miura NH, Mazda T, Tomita M. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem (Tokyo) 1996;120(4):803-12. (Pubitemid 26385421)
17. Nguyen MT, Satoh H, Favelyukis S, Babendure JL, Imamura T, Sbodio JI, et al. JNK and tumor necrosis factor-alpha mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes. J Biol Chem 2005;280(42):35361-71. (Pubitemid 41532725)
18. Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 1998;101(6):1354-61. (Pubitemid 28145252)
19. Olefsky JM. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J Clin Invest 2000;106(4):467-72. (Pubitemid 30666379)
20. Sakamoto J, Kimura H, Moriyama S, Odaka H, Momose Y, Sugiyama Y, et al. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 2000;278(3):704-11.
21. Sakoda H, Ogihara T, Anai M, Fujishiro M, Ono H, Onishi Y, et al. Activation of AMPK is essential for AICAR-induced glucose uptake by skeletal muscle but not adipocytes. Am J Physiol Endocrinol Metab 2002;282(6):E1239-44.
22. Salt IP, Connell JM, Gould GW. 5-Aminoimidazole-4-carboxamide ribonucleoside (AICAR) inhibits insulin-stimulated glucose transport in 3T3-L1 adipocytes. Diabetes 2000;49(10):1649-56.
23. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001;414(6865):799-806. (Pubitemid 34000783)
24. Satoh H, Nguyen MT, Miles PD, Imamura T, Usui I, Olefsky JM. Adenovirus-mediated chronic "hyper-resistinemia" leads to in vivo insulin resistance in normal rats. J Clin Invest 2004;114(2):224-31.
25. Satoh H, Nguyen MT, Trujillo M, Imamura T, Usui I, Scherer PE, et al. Adenovirus-mediated adiponectin expression augments skeletal muscle insulin sensitivity in male Wistar rats. Diabetes 2005;54(5):1304-13. (Pubitemid 40586658)
26. Scherer PE. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 2006;55(6):1537-45. (Pubitemid 44324105)
27. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995;270(45): 26746-9.
28. Shimizu A, Takamura T, Matsuzawa N, Nakamura S, Nabemoto S, Takeshita Y, et al. Regulation of adiponectin receptor expression in human liver and a hepatocyte cell line. Metabolism 2007;56(11):1478-85. (Pubitemid 47562497)
29. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998;47(4):507-14. (Pubitemid 28160438)
30. Standaert ML, Galloway L, Karnam P, Bandyopadhyay G, Moscat J, Farese RV. Protein kinase C-zeta as a downstream effector of phosphatidylinositol 3-kinase during insulin stimulation in rat adipocytes. Potential role in glucose transport. J Biol Chem 1997;272(48):30075-82. (Pubitemid 27512203)
31. Tan GD, Debard C, Funahashi T, Humphreys SM, Matsuzawa Y, Frayn KN, et al. Changes in adiponectin receptor expression in muscle and adipose tissue of type 2 diabetic patients during rosiglitazone therapy. Diabetologia 2005;48(8):1585-9. (Pubitemid 41175512)
32. Tsuchida A, Yamauchi T, Ito Y, Hada Y, Maki T, Takekawa S, et al. Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem 2004;279(29):30817-22. (Pubitemid 38938015)
33. Tsuchida A, Yamauchi T, Takekawa S, Hada Y, Ito Y, Maki T, et al. Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination. Diabetes 2005;54(12):3358-70. (Pubitemid 43334324)
34. Tzameli I, Fang H, Ollero M, Shi H, Hamm JK, Kievit P, et al. Regulated production of a peroxisome proliferator-activated receptor-gamma ligand during an early phase of adipocyte differentiation in 3T3-L1 adipocytes. J Biol Chem2004;279(34):36093-102.
35. Vaxillaire M, Dechaume A, Vasseur-Delannoy V, Lahmidi S, Vatin V, Lepretre F, et al. Genetic analysis of ADIPOR1 and ADIPOR2 candidate polymorphisms for type 2 diabetes in the Caucasian population. Diabetes 2006;55(3):856-61. (Pubitemid 43343248)
36. Wang C, Mao X, Wang L, Liu M, Wetzel MD, Guan KL, et al. Adiponectin sensitizes insulin signaling by reducing p70 S6 kinase-mediated serine phosphorylation of IRS-1. J Biol Chem 2007;282(11):7991-6. (Pubitemid 47093602)
37. Wu X, Motoshima H, Mahadev K, Stalker TJ, Scalia R, Goldstein BJ. Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes. Diabetes 2003;52(6):1355-63. (Pubitemid 36666188)
38. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7(8):941-6. (Pubitemid 32756432)
39. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8(11):1288-95. (Pubitemid 35373562)
40. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003;423(6941): 762-9. (Pubitemid 36735700)
41. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007;13(3):332-9. (Pubitemid 46376688)